Timothy L Cannon
Overview
Explore the profile of Timothy L Cannon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qi C, Shen L, Andre T, Chung H, Cannon T, Garralda E, et al.
Eur J Cancer
. 2025 Mar;
220:115338.
PMID: 40068370
Background: Larotrectinib is the first-in-class, highly selective TRK inhibitor with demonstrated efficacy in various TRK fusion solid tumours. We report the efficacy and safety of larotrectinib in patients with TRK...
2.
Ahn D, Ridinger M, Cannon T, Mendelsohn L, Starr J, Hubbard J, et al.
J Clin Oncol
. 2024 Oct;
43(7):840-851.
PMID: 39475591
Purpose: This phase II study evaluated the efficacy and tolerability of onvansertib, a polo-like kinase 1 (PLK1) inhibitor, in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) + bevacizumab for the...
3.
Worden F, Pisick E, Rothe M, Mangat P, Garrett-Mayer E, Khalil M, et al.
JCO Precis Oncol
. 2024 Oct;
8:e2400477.
PMID: 39413339
Purpose: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and targetable genomic...
4.
Johnston L, Randall J, Chouraichi S, Luu M, Hunt A, Mauro L, et al.
NPJ Precis Oncol
. 2024 Sep;
8(1):203.
PMID: 39277699
Recent trials have shown the efficacy of trastuzumab deruxtecan (T-DXd) in HER2-negative patients, but there is not yet a way to identify which patients will best respond, especially with the...
5.
Chaudhary H, Cannon T, Winer A
Drugs R D
. 2024 Aug;
24(3):395-403.
PMID: 39177935
Background And Objective: While successful treatment paradigms for BRAF V600 mutations have been developed, 10% of BRAF mutations are not at V600 and lack a standard treatment regimen. This study...
6.
Cannon T, Rothe M, Mangat P, Garrett-Mayer E, Chiu V, Hwang J, et al.
J Clin Oncol
. 2024 May;
42(27):3228-3237.
PMID: 38748939
Purpose: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations...
7.
Randall J, Hunt A, Nutcharoen A, Johnston L, Chouraichi S, Wang H, et al.
Clin Proteomics
. 2024 Mar;
21(1):24.
PMID: 38509475
Metastatic pancreatic adenocarcinoma (PDAC) is the third leading cause of cancer-related death in the United States, with a 5-year survival rate of only 11%, necessitating identification of novel treatment paradigms....
8.
Meric-Bernstam F, Rothe M, Mangat P, Garrett-Mayer E, Gutierrez R, Ahn E, et al.
JCO Precis Oncol
. 2023 Dec;
7:e2300385.
PMID: 38096472
Purpose: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers with genomic...
9.
Duvivier H, Rothe M, Mangat P, Garrett-Mayer E, Ahn E, Baghdadi T, et al.
J Clin Oncol
. 2023 Aug;
41(33):5140-5150.
PMID: 37561967
Purpose: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a pragmatic basket trial evaluating antitumor activity of approved targeted agents in patients with advanced cancers harboring potentially actionable...
10.
Hunt A, Nutcharoen A, Randall J, Papazian A, Deeken J, Maxwell G, et al.
Oncologist
. 2023 May;
28(8):730-736.
PMID: 37255276
Inflammatory myofibroblastic tumors (IMTs) are intermediate-grade mesenchymal neoplasms commonly characterized by chromosomal rearrangements causing constitutive activation of anaplastic lymphoma kinase (ALK) and/or ALK mutations causing reduced sensitivity to ALK tyrosine...